The FDA approved the experimental Alzheimer's drug donanemab. The drug will be sold under the brand name Kisunla.
  • I_Fart_Glitter@lemmy.worldEnglish
    0·
    3 days ago

    I guess I shouldn’t expect too much from USA Today, but it seems like pretty poor reporting to tell us that five people in the study died from side effects, but not say how many people were in the study. It’s kind of important.